Panagiotis Roussos, MD, PhD
Panagiotis (Panos) Roussos, MD, PhD, is Director of the Center for Precision Medicine and Translational Therapeutics at the James J. Peters VA Medical Center and a core investigator within the VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC). In these roles, he leads Veteran-focused translational research programs aimed at understanding and reducing risk for serious mental illness, suicide, and neurodegenerative disorders through precision medicine and AI-enabled analytic approaches. He is also the Endowed Chair of Translational Psychiatry, Professor of Psychiatry and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, and Director of the Center for Disease Neurogenomics. Dr. Roussos leads large-scale national and international research initiatives that integrate genomics, single-cell and spatial biology, advanced AI/ML methods, and clinical data to advance biologically informed, data-driven mental health care for Veterans and the broader population.
Research Interests
Schizophrenia, genetics, precision medicine, artificial intelligence
Grants
Higher Order Chromatin and Genetic Risk for Alzheimer's Disease (2021-2026)
Role: Principal investigator. Funding source: NIH/NIA
Multiethnic genomic, epigenomic and transcriptomic fine-mapping and functional validation analysis of schizophrenia and bipolar disorder risk loci (2021-2025)
Role: Principal investigator. Funding source: NIH/NIMH
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer Disease (2020-2025)
Role: Principal investigator. Funding source: NIH/NIA
A regulome and transcriptome atlas of fetal and adult human neurogenesis (2021-2024)
Role: Contact Principal investigator. Funding source: NIH/NIMH
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer Disease (2019-2024)
Role: Contact Principal investigator. Funding source: NIH/NIA
The 3D genome in transcriptional regulation across the postnatal life span, with implications for schizophrenia and bipolar disorder (2018-2023)
Role: Contact Principal investigator. Funding source: NIH/NIMH
Single-nucleus transcriptome profiling across multiple brain regions in Parkinson's Disease (2021-2022)
Role: Contact Principal investigator. Funding source: NIH/NINDS
In the News
Scientists Pinpoint What Makes Brain Cells Develop In A Specific Order (ScienMag, April 2022)
Researchers Identify Specific Genes That Play Key Role In Schizophrenia (ScienMag, April 2022)
Study identifies chromatin alterations in the brains of patients with schizophrenia and bipolar disorder (MedicalXpress, April 2022)
New Approach Identifies Candidate Causal Variants for Neuropsychiatric, Neurodevelopmental Conditions (Genomeweb, January 2022)
COVID Smell Loss and Long COVID Linked to Inflammation (Scientific American Podcast: Science Talk, February 2022)
Featured Publications
Below is a selection of Dr. Roussos’ publications; the full list can be found here.
Kosoy R, Fullard JF, Zeng B, Bendl J, Dong P, Rahman S, Steven Kleopoulos S, Shao Z, Humphrey J, de Paiva Lopes K, Charney A, Kopell B, Raj T, Bennett D, Kellner CP, Haroutunian V, Hoffman GE, Roussos P. Genetics of the human microglia regulome refines Alzheimer's disease risk loci. Nature Genetics, 2022.
Zeng B, Bendl J, Kosoy R, Fullard JF, Hoffman GE, Roussos P. Multi-ancestry eQTL meta-analysis of human brain identifies candidate causal variants for brain-related traits. Nature Genetics, 2022.
Konstantinides N, Holguera I, Rossi AM, Escobar A, Dudragne L, Chen YC, Tran TN, Martínez Jaimes AM, Özel MN, Simon F, Shao Z, Tsankova NM, Fullard JF, Walldorf U, Roussos P, Desplan C. A complete temporal transcription factor series in the fly visual system. Nature, 2022.
Fullard JF, Lee HC, Voloudakis G, Suo S, Javidfar B, Shao Z, Peter C, Zhang W, Jiang S, Corvelo A, Wargnier H, Woodoff-Leith E, Purohit DP, Ahuja S, Tsankova NM, Jette N, Hoffman GE, Akbarian S, Fowkes M, Crary JF, Yuan GC, Roussos P. Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19. Genome Medicine, 2021.
Hauberg ME, Creus-Muncunill J, Bendl J, Kozlenkov A, Zeng B, Corwin C, Chowdhury S, Kranz H, Hurd YL, Wegner M, Børglum AD, Dracheva S, Ehrlich ME, Fullard JF, Roussos P. Common schizophrenia risk variants are enriched in open chromatin regions of human glutamatergic neurons. Nature Communications, 2020.
